CardioGenics Holdings EBIT

CardioGenics Holdings posts a EBIT of $-770K as of January 2016. That compares with $-920K in the prior-year period — up 16.3% year over year. That is below the sector sector average of $2.6T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CardioGenics Holdings's EBIT was $-920K. The latest reading is $-770K — a 16.3% year-over-year increase (period ending January 2016). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $2.6T is typical. CardioGenics Holdings's $-770K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of CardioGenics Holdings's financial statement story. At $-770K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CGNH's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $2.6T), and (3) consistency with growth and profitability. This page covers the first two; CardioGenics Holdings's other metric pages and overview cover the third.